These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2049750)

  • 1. A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic.
    Ingle JN; Mailliard JA; Schaid DJ; Krook JE; Gesme DH; Windschitl HE; Pfeifle DM; Etzell PS; Gerstner JG; Long HJ
    Cancer; 1991 Jul; 68(1):34-9. PubMed ID: 2049750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis.
    Ingle JN; Twito DI; Schaid DJ; Cullinan SA; Krook JE; Mailliard JA; Tschetter LK; Long HJ; Gerstner JG; Windschitl HE
    Cancer; 1991 Feb; 67(4):886-91. PubMed ID: 1991261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
    Ingle JN; Suman VJ; Mailliard JA; Kugler JW; Krook JE; Michalak JC; Pisansky TM; Wold LE; Donohue JH; Goetz MP; Perez EA
    Breast Cancer Res Treat; 2006 Jul; 98(2):217-22. PubMed ID: 16538529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer.
    Ingle JN; Twito DI; Schaid DJ; Cullinan SA; Krook JE; Mailliard JA; Marschke RF; Long HJ; Gerstner JG; Windschitl HE
    J Clin Oncol; 1988 May; 6(5):825-31. PubMed ID: 3284975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma.
    Ingle JN; Suman VJ; Kardinal CG; Krook JE; Mailliard JA; Veeder MH; Loprinzi CL; Dalton RJ; Hartmann LC; Conover CA; Pollak MN
    Cancer; 1999 Mar; 85(6):1284-92. PubMed ID: 10189133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study.
    Pyrhönen S; Valavaara R; Modig H; Pawlicki M; Pienkowski T; Gundersen S; Bauer J; Westman G; Lundgren S; Blanco G; Mella O; Nilsson I; Hietanen T; Hindy I; Vuorinen J; Hajba A
    Br J Cancer; 1997; 76(2):270-7. PubMed ID: 9231932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effect of tamoxifen alone versus tamoxifen in combination wtih gestagen and oestrogen in advanced breast cancer.
    Mouridsen HT; Palshof T; Rose C
    Recent Results Cancer Res; 1980; 71():169-77. PubMed ID: 6988913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toremifene and tamoxifen in advanced breast cancer--a double-blind cross-over trial.
    Stenbygaard LE; Herrstedt J; Thomsen JF; Svendsen KR; Engelholm SA; Dombernowsky P
    Breast Cancer Res Treat; 1993; 25(1):57-63. PubMed ID: 8518408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
    Byrne MJ; Gebski V; Forbes J; Tattersall MH; Simes RJ; Coates AS; Dewar J; Lunn M; Flower C; Gill PG; Stewart J
    J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
    Ingle JN; Suman VJ; Johnson PA; Krook JE; Mailliard JA; Wheeler RH; Loprinzi CL; Perez EA; Jordan VC; Dowsett M
    Clin Cancer Res; 1999 Jul; 5(7):1642-9. PubMed ID: 10430063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
    Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
    J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of adjuvant tamoxifen combined with postoperative radiation therapy or adjuvant chemotherapy in postmenopausal breast cancer.
    Rutqvist LE; Cedermark B; Glas U; Johansson H; Rotstein S; Skoog L; Somell A; Theve T; Wilking N; Askergren J
    Cancer; 1990 Jul; 66(1):89-96. PubMed ID: 2191764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure.
    Ingle JN; Green SJ; Ahmann DL; Edmonson JH; Nichols WC; Frytak S; Rubin J
    Cancer Res; 1982 Aug; 42(8 Suppl):3461s-3467s. PubMed ID: 7044529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen and oophorectomy in the treatment of recurrent breast cancer: a Southwest Oncology Group Study.
    Hoogstraten B; Fletcher WS; Gad-el-Mawla N; Maloney T; Altman SJ; Vaughn CB; Foulkes MA
    Cancer Res; 1982 Nov; 42(11):4788-91. PubMed ID: 7127314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effect of tamoxifen related to estrogen receptor level.
    Rose C; Thorpe SM; Løber J; Daenfeldt JL; Palshof T; Mouridsen HT
    Recent Results Cancer Res; 1980; 71():134-41. PubMed ID: 6988911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
    Thürlimann B; Hess D; Köberle D; Senn I; Ballabeni P; Pagani O; Perey L; Aebi S; Rochlitz C; Goldhirsch A
    Breast Cancer Res Treat; 2004 Jun; 85(3):247-54. PubMed ID: 15111763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group.
    Wils JA; Bliss JM; Marty M; Coombes G; Fontaine C; Morvan F; Olmos T; Pérez-López FR; Vassilopoulos P; Woods E; Coombes RC
    J Clin Oncol; 1999 Jul; 17(7):1988-98. PubMed ID: 10561249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis.
    Peethambaram PP; Ingle JN; Suman VJ; Hartmann LC; Loprinzi CL
    Breast Cancer Res Treat; 1999 Mar; 54(2):117-22. PubMed ID: 10424402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer.
    Hayes DF; Van Zyl JA; Hacking A; Goedhals L; Bezwoda WR; Mailliard JA; Jones SE; Vogel CL; Berris RF; Shemano I
    J Clin Oncol; 1995 Oct; 13(10):2556-66. PubMed ID: 7595707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia.
    J Clin Oncol; 1986 Feb; 4(2):186-93. PubMed ID: 2868074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.